LITTLE GREEN PHARMA LTD — Director's Dealing 2021

Mar 11, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Little Green Pharma Ltd ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Angus McDougall Caithness
Date of last notice	17 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct & indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Banquo Consulting Pty Ltd - Mr Caithness is a director
Date of change		12 March 2021
No. of securities held prior to change		Direct 177,491 Ordinary shares 3,500,000 Options exercisable at 30 cents, expiring 28 February 2022 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights 115,516 Director Share Rights Indirect 5,500,000 Ordinary shares
Class		Fully paid ordinary shares
Number acquired		(a) 500,000 (b) 71,782 (c) 115,516
Number disposed		Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		(a) Nil consideration. Issued upon conversion of Performance Rights:- - 166,666 Class C Performance Rights - 166,667 Class D Performance Rights - 166,667 Class E Performance Rights (b) Deemed consideration of $39,420, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021. (c) Nil consideration. Issued on exercise of Director Share Rights, which wereissued on 17December 2020
No. of securities held after change		Direct 864,789 Ordinary shares 3,500,000 Options exercisable at 30 cents, expiring 28 February 2022 333,334 Class C Performance Rights 333,333 Class D Performance Rights 333,333 Class E Performance Rights Indirect 5,500,000 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		(a) Issue of fully paid ordinary shares upon satisfaction of Performance Rights milestones, being:- - Class C Performance Rights – upon the Company’s 20-day VWAP equalling or exceeding $0.55 before 4 February 2023 - Class D Performance Rights – upon the Company’s 20-day VWAP equalling or exceeding $0.65 before 4 February 2023 - Class E Performance Rights - upon the Company’s 20-day VWAP equalling or exceeding $0.75 before 4 February 2023 (b) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders (c) Issued on exercise of Director Share Rights as detailed above

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to whichtheinteresthas changed

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Little Green Pharma Ltd ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	17 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	12 March 2021
No. of securities held prior to change	19,600,000 fully paid ordinary shares 500,000 Class C Performance Rights 500,000 Class D Performance Rights 500,000 Class E Performance Rights 114,716 Director Share Rights
Class	Fully paid ordinary shares
Number acquired	(a) 500,000 (b) 40,723 (c) 114,716

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Nil consideration. Issued upon conversion of Performance Rights:- - 166,666 Class C Performance Rights - 166,667 Class D Performance Rights - 166,667 Class E Performance Rights (b) Deemed consideration of $22,363 being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021. (c) Nil consideration. Issued on exercise of Director Share Rights, which were issued on 17 December 2020
No. of securities held after change	20,255,439 fully paid ordinary shares 333,334 Class C Performance Rights 333,333 Class D Performance Rights 333,333 Class E Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Issue of fully paid ordinary shares upon satisfaction of Performance Rights milestones, being:- - Class C Performance Rights – upon the Company’s 20-day VWAP equalling or exceeding $0.55 before 4 February 2023 - Class D Performance Rights – upon the Company’s 20-day VWAP equalling or exceeding $0.65 before 4 February 2023 - Class E Performance Rights - upon the Company’s 20-day VWAP equalling or exceeding $0.75 before 4 February 2023 (b) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders (c) Issued on exercise of Director Share Rights as detailed above

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Little Green Pharma Ltd ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael David Lynch-Bell
Date of last notice	17 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	12 March 2021
No. of securities held prior to change	600,000 Ordinary shares 300,000 Retention Share Rights 150,917 Director Share Rights
Class	Fully paid ordinary shares
Number acquired	(a) 82,826 (b) 150,917
Number disposed	Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Deemed consideration of $45,485, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021. (b) Nil consideration. Issued on exercise of Director Share Rights, which were issued on 17 December 2020
No. of securities held after change	833,743 Ordinary shares 300,000 Retention Share Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders (b) Issued on exercise of Director Share Rights as detailed above

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Little Green Pharma Ltd ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neale William Fong
Date of last notice	17 December 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee
Date of change	12 March 2021
No. of securities held prior to change	Riverpalm Pty Ltd 250,000 Ordinary shares Dr Neale Fong 675,000 Ordinary shares 150,000 Retention Share Rights 75,458 Director Share Rights
Class	Fully paid ordinary shares
Number acquired	41,413

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Deemed consideration of $22,742, being forgiven salary for the period 1 November 2020 to 28 February 2021. Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed in notice of meeting dated 27 October 2020 and Appendix 2A dated 12 March 2021.
No. of securities held after change	Riverpalm Pty Ltd 250,000 Ordinary shares Dr Neale Fong 716,413 Ordinary shares 150,000 Retention Share Rights 75,458 Director Share Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation inbuy-back	Issued on concurrent issue and exercise of Director Share Rights granted in lieu of salary as detailed above and previously approved by shareholders

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002